SEARCH

SEARCH BY CITATION

References

  • Buyse, M., Squifflet, P., Lange, B.J., Alonzo, T.A., Larson, R.A., Kolitz, J.E., George, S.L., Bloomfield, C.D., Castaigne, S., Chevret, S., Blaise, D., Maraninchi, D., Lucchesi, K.J. & Burzykowski, T. (2011) Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood, 117, 70077013.
  • Decker, T., Bogner, C., Oelsner, M., Peschel, C. & Ringshausen, I. (2010) Antiapoptotic effect of interleukin-2 (IL-2) in B-CLL cells with low and high affinity IL-2 receptors. Annals of hematology, 89, 11251132.
  • Koreth, J., Matsuoka, K.-I., Kim, H.T., McDonough, S.M., Bindra, B., Alyea, E.P., Armand, P., Cutler, C., Ho, V.T., Treister, N.S., Bienfang, D.C., Prasad, S., Tzachanis, D., Joyce, R.M., Avigan, D.E., Antin, J.H., Ritz, J. & Soiffer, R.J. (2011) Interleukin-2 and regulatory T cells in graft-versus-host disease. The New England Journal of Medicine, 365, 20552066.
  • Meloni, G., Vignetti, M., Pogliani, E., Invernizzi, R., Allione, B., Mirto, S., Sica, S., Leoni, F., Selleri, C. & Mandelli, F. (1999) Interleukin-2 therapy in relapsed acute myelogenous leukemia. The Cancer Journal from Scientific American, 40, 7780.
  • Paietta, E., Racevskis, J., Neuberg, D., Rowe, J.M., Goldstone, A.H. & Wiernik, P.H. (1997) Expression of CD25 (interleukin-2 receptor α chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR/ABL fusion transcripts: results of a preliminary laboratory analysis of ECOG/MRC Intergroup Study E2993. Leukemia, 11, 18871890.
  • Pardee, T.S., Zuber, J. & Lowe, S.W. (2011) Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner. Experimental Hematology, 39, 473485.
  • Patel, J.P., Gönen, M., Figueroa, M.E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., Huberman, K., Cheng, J., Viale, A., Socci, N.D., Heguy, A., Cherry, A., Vance, G., Higgins, R.R., Ketterling, R.P., Gallagher, R.E., Litzow, M., van den Brink, M.R., Lazarus, H.M., Rowe, J.M., Luger, S., Ferrando, A., Paietta, E., Tallman, M.S., Melnick, A., Abdel-Wahab, O., & Levine, R.L. (2012) Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. The New England Journal of Medicine, 366, 111.
  • Ramanathan, M., Zhou, Z., Cerny, J., Raffel, G.D., Petrillo-Deluca, L., Walsh, W.V., Bathini, V., Vail, M., Smethers, K., Woda, B., Miron, P., Rosmarin, A.G. & Nath, R. (2010) High Complete Remission (CR) Rates and Reduced Early Mortality with High Dose Ara-c (HiDAC) and Mitoxantrone (MITO) Induction Chemotherapy for Older (age>60) High Risk Patients with Acute Myeloid Leukemia (AML). Blood (ASH Annual Meeting Abstracts), 116, 3290.
  • Saito, Y., Kitamura, H., Hijikata, A., Tomizawa-Murasawa, M., Tanaka, S., Takagi, S., Uchida, N., Suzuki, N., Sone, A., Najima, Y., Ozawa, H., Wake, A., Taniguchi, S., Shultz, L.D., Ohara, O. & Ishikawa, F. (2010) Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Science translational medicine, 2, 17ra9.
  • Terwijn, M., Feller, N., Van Rhenen, A., Kelder, A., Westra, G., Zweegman, S., Ossenkoppele, G. & Schuurhuis, G.J. (2009) Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML. European Journal of Cancer, 45, 16921699.